Castle Biosciences (CSTL) to Release Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is projected to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $81.1890 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Castle Biosciences Price Performance

Shares of CSTL opened at $33.67 on Thursday. Castle Biosciences has a 52 week low of $14.59 and a 52 week high of $44.28. The company has a current ratio of 6.47, a quick ratio of 6.31 and a debt-to-equity ratio of 0.02. The firm has a market cap of $982.83 million, a price-to-earnings ratio of -74.82 and a beta of 1.06. The stock has a 50 day moving average of $38.40 and a 200-day moving average of $30.66.

Insider Activity at Castle Biosciences

In related news, COO Kristen M. Oelschlager sold 14,888 shares of Castle Biosciences stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total transaction of $585,247.28. Following the sale, the chief operating officer directly owned 12,323 shares in the company, valued at $484,417.13. The trade was a 54.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 817 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $37.99, for a total transaction of $31,037.83. Following the completion of the sale, the insider directly owned 83,698 shares of the company’s stock, valued at $3,179,687.02. The trade was a 0.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 34,732 shares of company stock worth $1,372,743. 6.50% of the stock is owned by insiders.

Institutional Trading of Castle Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. acquired a new stake in Castle Biosciences in the fourth quarter worth approximately $35,000. Jones Financial Companies Lllp boosted its stake in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Castle Biosciences by 256.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,791 shares of the company’s stock valued at $57,000 after purchasing an additional 2,009 shares during the period. Finally, Russell Investments Group Ltd. increased its position in shares of Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after purchasing an additional 976 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CSTL has been the subject of several recent research reports. KeyCorp reiterated an “overweight” rating and set a $50.00 target price on shares of Castle Biosciences in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Canaccord Genuity Group lifted their target price on Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Guggenheim increased their price target on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research boosted their price objective on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.14.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.